Before changing an inherited facility or design, a written gap assessment against the URS and target regulations gives management and inspectors the same picture: evidence from documents and spot measurements, findings graded by risk, and the fix, cost range and schedule impact of each, plus what can stay.
EU GMP Annex 15 (2015) treats three consecutive PPQ batches as a common minimum, with the number justified from risk; the FDA's 2011 guidance names no count and works in three stages. A rationale that serves both draws on commercial-scale variability, parameters near their proven limits, prior knowledge and a statistical target on the CQAs.
21 CFR 211.42 and 211.46 and EU GMP Chapter 3 ask for adequate ventilation, air control and filtration, but give no air change rate or pressure differential, and no filter class beyond HEPA for aseptic areas. Those come from Annex 1, FDA's 2004 aseptic guidance, ISO 14644 and the designer's justification, recorded in the design basis.
Annex 1 (2022) sets Grade A microbial limits as no growth and requires any growth to be investigated; FDA's 2004 aseptic guidance gives ISO 5 action levels of 1 CFU/m³ and 1 CFU per 4-hour settle plate. A plant filing in both markets can write one stricter rule and one investigation route.
FED-STD-209E was cancelled in 2001, but Class 100, 10,000 and 100,000 survive in URS documents via the FDA's 2004 guidance, which maps them to ISO 5, 7 and 8 in operation. Write the ISO class, particle size, occupancy state and EU grade so nothing is left to guess.
FDA's 2004 aseptic guidance asks for at least 10–15 Pa between rooms of different classification; Annex 1 gives at least 10 Pa as guidance. Setting each cascade step at 15 Pa meets both. Holding it is harder: seals wear and filters load, so trend the differentials instead of waiting for alarms.
MHRA (March 2018), FDA Q&A (December 2018), PIC/S PI 041-1 (July 2021) and WHO TRS 1033 Annex 4 (2021) all rest on ALCOA+. The difference that matters in a response is who wrote each one and for whom, so cite first the text the inspector works from.
Part 11 applies to electronic records that a predicate rule such as 21 CFR 211 requires. For a BMS or EMS, name the rule behind each point: GMP-critical monitoring usually belongs in a validated EMS. For EU export, Annex 11 has no predicate-rule test, so the BMS still needs a risk assessment.
FDA's 2018 data integrity Q&A separates static records from dynamic ones. A printed EMS trend keeps one view and leaves raw values, metadata and the audit trail behind. Keep the electronic original for the retention period, have the reviewer work in the system, and label printouts as convenience copies.
Scripted CSV evidences every step of a BMS pressure alarm test. FDA's Computer Software Assurance guidance keeps scripted tests for high-risk checks such as setpoint, delay and the audit record, then adds unscripted testing of failure modes, recorded by what was tried and what happened.
Annex 11 asks for audit trails to be regularly reviewed but gives no list. On an EMS or BMS, filter for deleted data, setpoint and alarm limit changes outside change control, alarms acknowledged without comment, repeated tests before a pass, and clock or role changes. Then a reviewer can sign for it.
The supply contract covers price and delivery. The quality agreement has to settle who is responsible for each GMP activity, how changes are notified and approved, how fast deviations and OOS results are reported, audit and subcontracting rights, and who keeps records and certifies the batch.